Last reviewed · How we verify
Microplasmin
At a glance
| Generic name | Microplasmin |
|---|---|
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | discontinued |
Approved indications
- Vitreomacular traction syndrome
Common side effects
Key clinical trials
- Treatment with Intravenous Alteplase in Ischemic Stroke Patients with Onset Time Between 4.5 and 24 Hours (Phase 3)
- Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital (Phase 4)
- A Randomized, Placebo Controlled, Double-masked, Multicenter Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. (Phase 3)
- Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage (Phase 1)
- A Randomized Controlled Trial of Intra-arterial Reperfusion Therapy After Standard Dose Intravenous t-PA Within 4.5 Hours of Stroke Onset Utilizing Dual Target Imaging Selection. (Phase 2)
- Mechanical Opening Device Implantation Following Intravenous r-tPA and Recanalization Outcome Evaluation in Stroke Disease (MODIFIED) Trial (Phase 2)
- NCT00000507 (Phase 3)
- TOP-TRIAL The Safety of Not Flushing the Non-used PORT-A-CATH® in Cancer Patients - a Prospective, Two-arm Phase I Trial, Pilot Trial (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Microplasmin CI brief — competitive landscape report
- Microplasmin updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI